Merck's Prilosec
Executive Summary
Is "approvable" for use in the short-term treatment of active duodenal ulcer poorly responsive to customary medical therapy. Merck reportedly received the approvable letter Dec. 26. An FDA advisory committee recommended approval for treatment of short- term acute and refractory duodenal ulcers in May 1990. The acid pump inhibitor was approved in 1989 for three limited indications: short-term treatment of severe erosive esophagitis, short-term treatment of symptomatic gastroesophageal reflux disease poorly responsive to customary medical treatment, and long-term treatment of Zollinger-Ellison syndrome.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth